Business, energy, technology, markets and global industry news from Business News Today

multispecific antibodies

PharmaDeviceNews multispecific antibodies
Representative image: Researchers use artificial intelligence and machine learning to design tumour-targeting multispecific antibodies, reflecting the LabGenius Therapeutics and LG Chem collaboration aimed at improving precision and safety in solid tumour treatment.
Pharma & Biotech

LabGenius-LG Chem deal tests whether AI can improve solid-tumour treatment precision

Discover how LabGenius and LG Chem aim to use AI-designed multispecific antibodies to reduce solid-tumour toxicity and reshape oncology R&D.

Read More
Representative image of scientists reviewing oncology research data in a modern biopharma laboratory, reflecting Pfizer and Innovent Biologics’ $10.5 billion collaboration and the growing race to develop antibody-drug conjugates and multispecific cancer therapies.
Pharma & Biotech

Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?

Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.

Read More
Representative image of oncology researchers reviewing molecular therapy data, reflecting Pfizer and Innovent Biologics’ global collaboration to advance antibody-drug conjugates, multispecific antibodies, and next-generation cancer medicines.
Pharma & Biotech

Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines

Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?

Read More
Pharma & Biotech

What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering

Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.

Read More
Pharma & Biotech

Can Harbour BioMed’s deal with Bristol Myers Squibb redefine the future of multispecific antibodies?

Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not

Read More